{"analyses":[{"ciLowerLimit":"0.724","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.086","estimateComment":"Stratified","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2461","pValueComment":"Stratified","paramType":"Hazard Ratio (HR)","paramValue":"0.887","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.89","upperLimit":"11.43","value":"9.40"},{"groupId":"OG001","lowerLimit":"7.00","upperLimit":"9.30","value":"7.85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"267"}],"units":"Participants"}],"description":"OS is the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date prior to the data inclusion cutoff date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"},{"description":"Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Placebo + Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Censored participants: Ramucirumab + Docetaxel = 78, Placebo + Docetaxel = 67.","reportingStatus":"POSTED","timeFrame":"Randomization to Date of Death from Any Cause (Up to 31.1 Months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}